[Therapeutic effect of tiotropium bromide powder inhalation in patients with stable bronchiectasis].
OBJECTIVE
To observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis.


METHODS
Twenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 microg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second (FEVl), predicted value [FEVl(%)], forced expiratory volume (FEV), and FEVl/FVC. The symptom score and BODE index were also recorded.


RESULTS
After 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant (t=-1.875, P>0.05); the symptom score and BODE index decreased significantly after the therapy (t=7.091, P<0.001; t=2.982, P<0.05).


CONCLUSIONS
Long-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.
Li
Xiao-ling
XL
Department of Respiratory Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. myxiao2000@126.com
Cai
Shao-xi
SX
Zhao
Hai-jin
HJ
Dong
Li-min
LM
Shen
Xiang-bo
XB
Liu
Lai-yu
LY
Hu
Guo-dong
GD
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D001987:Bronchiectasis / Q000188:drug therapy*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D011208:Powders; D043587:Receptor, Muscarinic M3 / Q000037:antagonists & inhibitors*; D012602:Scopolamine Derivatives / Q000008:administration & dosage*; D000069447:Tiotropium Bromide
D011208:Powders; D043587:Receptor, Muscarinic M3; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide